Guillermo Garcia-Manero, M.D.

Guillermo Garcia-Manero, M.D., is an Associate Internist and Associate Professor of Medicine. He serves as the chief of the Section of Myelodysplastic Syndromes in the Department of Leukmia. He joined the department in 1999 when he arrived in Houston from Philadelphia. Dr. Garcia-Manero received his medical degree from the Faculty of Medicine of the University of Zaragoza in Spain. He then served as Intern and Resident at Thomas Jefferson University Hospital in Philadelphia. He completed his fellowship in Hematology and Medical Oncology at the Cardeza Foundation for Hematological Research and the Kimmel Cancer Center; both at Thomas Jefferson University, where he also served as Chief Fellow. Dr. Garcia-Manero is board certified in Internal Medicine and Medical Oncology. His interests are the treatment of acute and chronic leukemias and myelodysplastic syndromes, as well as the molecular aspects of these disorders and particularly the role of epigenetic alterations in leukemia.

Dr. Garcia-Manero is the recipient of several awards, including a Research Award for Clinical Trainees Program from the National Institutes of Health, a Career Development award from the American Society of Clinical Oncology, and the Physician Scientist award from M. D. Anderson. He is also the author of more than 160 publications, has been speaker in multiple international forums and is the recipient of several grants, including some from the NIH. To contact Dr. Garcia-Manero please call (713) 745- 3428 or e-mail ggarciam@mdanderson.org.

Honors & Awards

• 2002 – Physician Scientist Program
• 2001 - American Society of Clinical Oncology Career Development Award
• 1998 - Delaware Valley Hematology/Oncology Research Competition
• 1994 - Research Award for Clinical Trainees Program, National Institutes of Health, Bethesda, USA
• 1991 - Fellowship of the European Society of Human Genetics, Leuven, Belgium
• 1991 - University of Zaragoza Research Student Award, Spain
• 1990 - University of Zaragoza Research Student Award, Spain

Selected Publications

Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM. Phase 1 study of the histone deacetylase inhibitor vorinostat(suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008 Feb 1;11(3):1060-6 Epub 2007 Oct 25.

Garcia-Manero G. Modifying the epigenome as a therapeutic strategy in myelodysplasia. Hematology Am Soc Hematol Educ Program 2007;2007:405-11.

Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007.

Kuang SQ, Ling X, Sanchez-Gonzalez B, Yang H, Andreeff M, Garcia-Manero G. Differential tumor suppressor properties and transforming growth factor-beta responsiveness of p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA methylation. Oncogene 2007;26(10):1439-48.

Hoshino K, Quintas-Cardama A, Yang H, Sanchez-Gonzalez B, Garcia-Manero G. Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia. Leukemia 2007;21(5):906-11.

Han X, Garcia-Manero G, McDonnell TJ, et al. HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol 2007;20(1):54-62.

Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, et al. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 2006;108(4):1174-82.

Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108(10):3271-9.

Canalli AA, Yang H, Jeha S, et al. Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia. Leuk Res 2005;29(8):881-5.

Bueso-Ramos C, Xu Y, McDonnell TJ, et al. Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status. J Clin Oncol 2005;23(17):3932-9.

Shen L, Toyota M, Kondo Y, et al. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood 2003;101(10):4131-6.